FDA.reportPublic FDA data

FOTIVDA 0.89 MG Oral Capsule

RxCUI
2534244
RxNorm name
FOTIVDA 0.89 MG Oral Capsule
Display name
FOTIVDA 0.89 MG Oral Capsule
Full name
FOTIVDA 0.89 MG Oral Capsule
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:24

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
de77155c-ecf2-4f15-9758-21d271449d83FOTIVDA 0.89 MG Oral Capsule [PSN] · tivozanib 0.89 MG Oral Capsule [Fotivda] [SBD] · Fotivda (as tivozanib hydrochloride 1 MG) 0.89 MG Oral Capsule [SY] · Fotivda 0.89 MG Oral Capsule [SY]413These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 202120251001